TG Therapeutics, Inc. (NASDAQ: TGTX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewswire
- Despite shrinking by US$192m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 131% over 5 years [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewswire
- TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 5/1/24 - Miss
TGTX
Sec Filings
- 5/6/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 4/29/24 - Form ARS
- TGTX's page on the SEC website